Short linear oligopeptide assembly introduces mass-transfer, sequential-hydrolysis, and product-partitioning problems that are not visible in a dipeptide test. This article proposes Z-Gly-Gly-Phe-Leu-OEt, a protected tetrapeptide precursor related to des-Tyr1-leucine enkephalin chemistry, as a model for paired-fraction electrochemical programming (PFEP). Literature establishes thermolysin-catalysed coupling of Z-Gly-Gly with Phe-Leu-OEt and shows that aqueous-organic phase design can materially alter yield and by-product formation. PFEP is proposed only as an ex situ source of analytically measured acid-base or ionic capacity for maintaining a defined interfacial reaction trajectory and for rapidly quenching the synthesis-dominant window. The peptide, enzyme, and organic phase remain outside the electrochemical cell. The experimental design normalizes interfacial area, mixing power, water activity, phase ratio, temperature, and substrate concentration, and includes a chemical reconstruction of every measured fraction attribute. Success requires a higher isolated mass-balanced tetrapeptide yield or a lower hydrolysis burden than optimized conventional operation. No experimental performance is asserted. Article type: Perspective, mechanistic hypothesis, and experimental framework. No experimental peptide yield, potency, clinical effect, or shelf-life evidence is reported.
No takes yet. Share an insight, caveat, or question.
Ilyan Kan (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: